Bacterial adhesion processes in urinary tract

Bacterial adhesion processes in the urinary tract represent the initial and essential stage of pathogenesis for urinary tract infections (UTIs), primarily involving the attachment of uropathogenic bacteria to the host's urothelial lining [1, 6]. This process is mediated by specialized bacterial surface structures, such as Type 1 and P fimbriae, which utilize adhesin proteins like FimH and PapG to bind to specific host receptors, including mannosylated uroplakins and galabiose-containing glycosphingolipids [3, 11]. FimH-mediated adhesion to the bladder surface is the most well-characterized interaction and is a major target for anti-adhesion therapies [6, 8]. By preventing this initial attachment, bacteria are unable to colonize the urinary tract or form protective biofilms, allowing them to be naturally eliminated through urine flow [5, 15]. Drugs targeting these processes include natural compounds like D-mannose and cranberry-derived proanthocyanidins, as well as synthetic small-molecule FimH antagonists such as GSK3882347 and siboflanstat [5, 7, 8]. These agents act as competitive inhibitors, mimicking the host receptors to occupy the binding sites on bacterial adhesins [3, 6]. Anti-adhesion therapy is considered a promising non-antibiotic approach that exerts less selective pressure for resistance compared to traditional bactericidal agents, although challenges remain regarding their efficacy in established infections and potential effects on the commensal microbiota [1, 8].

Other names

Bacterial attachmentUropathogenic adhesionAnti-adhesion therapy targetFimH-mediated adhesionP-fimbriae-mediated adhesion

Competitive inhibition of bacterial adhesins (e.g., FimH, PapG) binding to host urothelial receptors (e.g., Uroplakin Ia), preventing bacterial colonization and facilitating clearance by urine flow.